statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaxart Stock Is Moving Higher After The Bell: What's Going On?

Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project...

FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain

FDA Changes Course, Advises Updated COVID-19 Vaccines Target KP.2 Strain

 Authored by Zachary Stieber via The Epoch Times (emphasis ours),
A healthcare worker prepares a COVID-19 vaccine...

Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering

Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID-19 vaccine study.
read more...

Vaxart Stock Climbs After Blockbuster Q1 Revenue

Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by...

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...

Vaxart, Inc. (NASDAQ:VXRT) Expected to Earn Q1 2024 Earnings of ($0.18) Per Share

Vaxart, Inc. (NASDAQ:VXRT  Free Report)  Equities research analysts at B. Riley issued their Q1 2024 earnings estimates for shares of Vaxart in a research note issued on Wednesday...

Research Analysts Offer Predictions for Vaxart, Inc.'s Q2 2024 Earnings (NASDAQ:VXRT)

Vaxart, Inc. (NASDAQ:VXRT  Free Report)  Equities researchers at B. Riley issued their Q2 2024 earnings estimates for shares of Vaxart in a note issued to investors on Wednesday, March...

Vaxart reports inducement grants under Nasdaq listing rule

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the Company or Vaxart ) today announced that the Compensation Committee of the Board of Directors...

Vaxart (NASDAQ:VXRT) Releases  Earnings Results, Beats Expectations By $0.03 EPS

Vaxart (NASDAQ:VXRT  Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus...

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in March 2004 and is headquartered in South San Francisco, CA.

Volume	1.22M
52-Wk High	$1.54
52-Wk Low	$0.52

VXRT Vaxart Inc

About

Feed

News

Sentiment

Earnings

Fundamentals